Leica LMD 7000 Laser Capture Microdissection Microscope

描述(由申请者提供)：这项仪器拨款提案要求为Leica LMD 7000激光显微解剖显微镜/系统提供资金，这是爱荷华大学(UI)正在进行的NIH支持的生物医学研究项目的关键工具。拟议的显微镜将提供高端能力，寻找和收集非常特定的、有针对性的细胞和组织样本，用于后续研究与公共卫生密切相关的人类疾病的分子遗传学和免疫学基础。UI目前有一台激光显微解剖显微镜服务于整个校园；然而，该仪器过时、难以使用、维修昂贵，而且最近经历了大量停机。显然，它需要被一种现代仪器取代，该仪器将足以用于参与这一应用的11名用户界面调查人员的研究，11名调查人员中有5人将使用LMD 7000 癌症研究方面：齐格弗里德·扬茨试图了解浆细胞肿瘤形成的遗传途径；安第斯·伯内特试图为头颈癌患者开发有针对性的治疗方法；Hasem Habelhah阐明了肿瘤细胞中cFlIP表达和RIP1切割的机制；George Weiner评估了用于淋巴瘤新治疗和预防方法的治疗性抗体；Dawn Quelle评估了PARF作为胰腺癌和脑癌预后生物标记物的潜在用途。11名研究人员中有6名将利用LMD 7000辅助激光显微切割进行与癌症无关的研究：Josef Comeller确定了单个染色体上的基因重组率；Jeffery Murray和Martle Dunnwald进行了唇腭裂形成的遗传学研究；David Stolz和Aliye UC检查了新发展的猪囊性纤维化模型中的器官损伤；Maureen Donovan研究了鼻黏膜中的转运蛋白，以改善向大脑的药物输送系统；David Soll评估了酵母和白色念珠菌的致病因素，这是免疫抑制患者机会性感染的常见根本原因。上述所有研究--目前得到了16,853,566美元NIH活跃研究资金的支持--都将从收购徕卡LMD 7000中受益匪浅。如果这项申请被授予，该系统将被设置在UI中央显微镜研究设施中。专门的设施人员将管理和维护仪器，提供高水平的技术援助和培训，并使其全天候可用，以容纳尽可能多的用户。这一申请享有强大的机构承诺，如所附的UI研究副总裁科恩博士和医学院院长罗斯曼博士的支持信所表明的那样。

DESCRIPTION (provided by applicant): This instrumentation grant proposal requests funds for a Leica LMD 7000 laser microdissection microscope/system, a critical tool for ongoing NIH-supported biomedical research projects at the University of Iowa (UI). The proposed microscope will provide high-end capabilities for seeking out and collecting very specific, targeted cell and tissue samples for follow-up studies on the molecular genetics and immunologic underpinnings of human diseases of great relevance for public health. The UI currently has one laser microdissection microscope to serve the entire campus; however, the instrument is obsolete, difficult to use, expensive to repair, and has recently experienced tons of downtime. Clearly, it needs to be replaced with a modern instrument that will be adequate for the research of the 11 UI investigators that take part in this application Five of 11 investigators will use the LMD 7000 for cancer research: Siegfried Janz seeks to understand the genetic pathways of plasma cell tumor formation; Andean Burnett attempts to develop targeted therapies for patients with head and neck cancer; Hasem Habelhah elucidates mechanisms of cFLIP expression and RIP1 cleavage in tumor cells; George Weiner evaluates therapeutic antibodies for use in novel lymphoma treatment and prevention approaches; and Dawn Quelle assesses the potential utility of PARF as a prognostic biomarker for pancreatic and brain cancer. 6 of 11 investigators will take advantage of LMD 7000-assisted laser microdissection for research unrelated to cancer: Josef Comeron determines genetic recombination rates along individual chromosomes; Jeffery Murray and Martine Dunnwald perform genetic studies on cleft lip and palate formation; David Stolz and Aliye Uc examine organ damage in a newly developed pig model of human cystic fibrosis; Maureen Donovan studies transporter proteins in the nasal mucosa for improved drug delivery systems to the brain; and David Soll evaluates factors of pathogenicity in the yeast, Candida albicans, the frequent underlying reason of opportunistic infections in immunosuppressed patients. All studies described above - currently supported by $16,853,566 of active NIH research funding - would greatly benefit from the acquisition of a Leica LMD 7000. If this application will be awarded, the system will be set up in the UI Central Microscopy Research Facility. Dedicated facility personnel will administer and maintain the instrument, provide high-level technical assistance and training, and make it available "24/7" in order to accommodate as many users as possible. This application enjoys strong institutional commitment, as demonstrated by attached letters of support from the UI VP for Research, Dr. Cohen, and the Dean of the College of Medicine, Dr. Rothman.